Risperidone Augmentation in the Treatment of Severe Adolescent OCD in SSRI-refractory Cases: A Case-series

References

• Geller DA, Hoog SL, Heiligenstein JH, Ricardi RK, Tamura R, Kluszynski S, Jacobson JG, Fluoxetine Pediatric OCD Study Team: Fluoxetine treatment of obsessive-compulsive disorder in children and adoles-cents: A placebo-controlled clinical trial. J Am Acad Child Adolesc Psychiatry 2001; 40:773–779.
   PubMed Web of Science ®Google Scholar
• Skoog G, Skoog I: A 40-year follow-up of patients with obsessive-compulsive disorder. Arch Gen Psych 1999; 56:121–127.
   PubMed Web of Science ®Google Scholar
• March JS, Biederman J, Wolkow R, Safferman A, Mardekian J, Cook EH, Cutler NR, Dominguez R, Ferguson J, Muller B, Riesenberg R, Rosenthal M, Sallee FR, Wagner KD: Sertraline in children and adolescents with obsessive-compulsive disorder: A multicenter randomized controlled trial. JAMA 1998; 280:1752–1756.
   PubMed Web of Science ®Google Scholar
• Liebowitz M, Turner SM, Piacentini J, Beidel DC, Clarvit SR, Davies S, Graae F, Jotter M, Lin S, Sallee FR, Schmidt AB, Simpson HB: Fluoxetine in children and adolescents with OCD: A placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 2002; 41:1431–1438.
   PubMed Web of Science ®Google Scholar
• Greist JH, Jenike MA, Robinson D, Rasmusen SA: Efficacy of fluvoxamine in obsessive-compulsive dis-order: Results of a multicentre, double blind, placebo-controlled trial. Eur J Clin Res 1995; 7:195–204.
   Google Scholar
• Thomsen P. Leckman J: Obsessive-compulsive dis-order and the anxiety spectrum in children. CNS Spectrums 2000; 5:18–23.
   Google Scholar
• Leonard HL, Swedo SE, Lenane M, Rettew DC, Hamburger SD, Bartko JJ, Rapoport IL: A two to seven year follow-up study of 54 obsessive compul-sive children and adolescents. Arch Gen Psych 1993; 50:429–439.
   PubMed Web of Science ®Google Scholar
• Thomsen PH, Mikkelsen HU: The addition of buspirone to SSRI in the treatment of adolescent obsessive-compulsive disorder. A study of six cases. Eur Child Adolesc Psychiatry 1999; 8:143–148.
   PubMed Web of Science ®Google Scholar
• March JS, Franklin M, Nelson A, Foa E: Cognitive-behavioral psychotherapy for pediatric obsessive-compulsive disorder. J Clin Child Psychol 2001; 30:8–18.
   PubMed Web of Science ®Google Scholar
• Greist JH, Bandelow B, Hollander E, Marazziti D, Montgomery SA, Nutt DJ, Okasha A, Swinson RP, Zohar J, World Council of Anxiety: WCA recomman-dations for the long-term treatment of obsessive-compulsive disorder in adults. CNS Spectrums 2003; 8:7–16.
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Fleischmann RL, Epperson CN, Wasylink S, Leckman IF, Price LH: Risperidone addi-tion in fluvoxamine-refractory obsessive-compulsive disorder: Three cases. J Clin Psychiatry 1995; 56:526–528.
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH: A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psych 2000; 57:794–801.
   PubMed Web of Science ®Google Scholar
• McDougle CJ, Goodman WK, Price LH: Dopamine antagonists in tic-related and psychotic spectrum obses-sive compulsive disorder. J Clin Psychiatry 1994; 55:24–31.
   PubMedGoogle Scholar
• Pfanner C, Marazziti D, Dell'Osso L, Presta S, Gemignani A, Milanfranchi A, Cassano GB: Risperi-done augmentation in refractory obsessive-compulsive disorder: An open-label study. Int Clin Psychopharmacol 2000; 15:297–301.
   PubMed Web of Science ®Google Scholar
• Fitzgerald KD, Stewart CM, Tawile V, Rosenberg DR: Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder. J Child Adolesc Psychopharm 1999; 9:115–123.
   PubMed Web of Science ®Google Scholar
• Findling RL, McNamara NK, Branicky LA, Schluchter MD, Lemon E, Blumer IL: A double-blind pilot study of risperidone in the treatment of conduct disorder. J Am Acad Child Adolesc Psychiatry 2000; 39:509–516.
   PubMed Web of Science ®Google Scholar
• Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL, Risperidone Disruptive Behavior Study Group: Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 2002; 159:1337–1346.
   PubMed Web of Science ®Google Scholar
• Goodman WK, Price LH, Rasmusen SA, Riddle M, Rapoport JL: Children 's Yale-Brown Obsessive Com-pulsive Scale (CY-BOCS). New Haven, Department of Psychiatry: Yale University School of Medicine, 1991.
   Google Scholar
• Goodman WK, Price LH, Rasmusen SA, Mazure C, Fleischman RL, Hill CL, Heninger GR, Charney DS: The Yale-Brown Obsessive Compulsive Scale. I. Develop-ment, use, and reliability. Arch Gen Psych 1989; 46:1006–1011.
   PubMed Web of Science ®Google Scholar
• Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N: Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 1997; 36:980–988.
   PubMed Web of Science ®Google Scholar
• Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, Aluwahlia S: A Children's Global Assessment Scale (CGAS). Arch Gen Psych 1983; 40:1228–1231.
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Kasper S, Stein DJ, Hedegaard KB, Lemming 0: Citalopram 20mg, 40mg and 60mg are all effective and well tolerated compared with placebo in obsessive compulsive disorder. Int Clin Psychophar-macol 2001; 16:75–86.
   PubMed Web of Science ®Google Scholar
• Thomsen PH: Child and adolescent obsessive-compulsive disorder treated with citalopram: Findings from an open-trial of 23 cases. J Child Adolesc Psychopharmacol 1997; 7:157–166.
   PubMed Web of Science ®Google Scholar
• Thomsen PH, Ebbesen C, Persson C: Long term experi-ence with citalopram in the treatment of adolescent OCD. J Am Acad Child Adolesc Psychiatry 2001; 40:895–902.
   PubMed Web of Science ®Google Scholar
• Cook EH, Wagner KD, March JS, Biederman J, Landau P, Wolkow R, Messig M: Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 2001; 40:1175–1181.
   PubMed Web of Science ®Google Scholar
• Ramasubbu R, Ravindran A, Lapierre Y: Serotonin and dopamine antagonistm in obsessive-compulsive dis-order: Effect of atypical antipsychotic drugs. Pharmaco-psychiatry 2000; 33:236–238.
   PubMed Web of Science ®Google Scholar
• Morrison D, Clark D, Goldfarb CE, McCoy L: Worsening of obsessive-compulsive symptoms following treatment with olanzapine. Am J Psych 1998; 155:855.
   PubMedGoogle Scholar
• Diler RS, Yolga A, Avci A, Scahill L: Risperidone-induced obsessive-compulsive symptoms in two chil-dren. J Child Adolesc Psychopharm 2003; 13:S89—S92.
   Google Scholar
• Maina G, Albert U, Ziero S, Bogetto F: Antipsychotic augmentation for treatment resistant obsessive-compulsive disorder: What if antipsychotic is discontinued? In Clin Psychopharmacol 2003; 18:23–28.
   PubMed Web of Science ®Google Scholar